Energenesis Biomedical Co Ltd
TWSE:6657
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| TW |
E
|
Energenesis Biomedical Co Ltd
TWSE:6657
|
4.4B TWD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
191.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.8B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.3B USD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.4B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -197.7% |
| 30th Percentile | 13.7% |
| Median | 22.1% |
| 70th Percentile | 31.4% |
| Max | 400.8% |
Other Profitability Ratios
Energenesis Biomedical Co Ltd
Glance View
Energenesis Biomedical Co., Ltd. engages in the development of new drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-08-08. The firm's main product projects include experimental service analysis and reagent sales. The firm's main new drugs include ENERGI-F703, ENERGI-F701, ENERGI-F711, and ENERGI-F706. The ENERGI-F703 indications are diabetic foot ulcers. The ENERGI-F701 indications are abnormal alopecia. The ENERGI-F711 indications are burns. The ENERGI-F706 indications are cachexia.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Energenesis Biomedical Co Ltd is 76%, which is above its 3-year median of 73.4%.
Over the last 3 years, Energenesis Biomedical Co Ltd’s Gross Margin has increased from 70.3% to 76%. During this period, it reached a low of 70.3% on Dec 1, 2022 and a high of 77.3% on Sep 30, 2025.
